Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD

Farzana Perwad; Anthony A Portale

doi:10.2215/CJN.15201218

Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD

Clin J Am Soc Nephrol. 2019 Jul 5;14(7):1097-1099. doi: 10.2215/CJN.15201218. Epub 2019 Jun 6.

Authors

Farzana Perwad¹, Anthony A Portale

Affiliation

¹ Division of Nephrology, Department of Pediatrics, University of California, San Francisco, California.

No abstract available

Keywords: CKD; FGF23; Familial Hypophosphatemic Rickets; Genetic Linkage; Hypophosphatemia, Familial; Renal Insufficiency, Chronic; Vitamin D; burosumab; phosphorus; rickets.

MeSH terms

Animals
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Familial Hypophosphatemic Rickets / drug therapy*
Fibroblast Growth Factor-23
Fibroblast Growth Factors / antagonists & inhibitors
Fibroblast Growth Factors / blood
Humans
Renal Insufficiency, Chronic / drug therapy*
Vitamin D / analogs & derivatives
Vitamin D / blood

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
FGF23 protein, human
Vitamin D
Fibroblast Growth Factors
1,25-dihydroxyvitamin D
Fibroblast Growth Factor-23
burosumab